1. The Kingdom of Saudi ArabiaTabuk
Tabuk Pharmaceuticals’ first manufacturing site was established 20 km from the city of Tabuk in the northwestern region of the Kingdom of Saudi Arabia. The total area of the site is about 100,000 square meters and the plant occupies over 35,000 square meters. Tabuk plant manufactures a wide range of pharmaceutical preparations such as tablets, capsules, and syrups, in addition to creams, ointments, and parenteral solutions. The site includes two separate buildings, one of which is dedicated to manufacture Cephalosporins. The site is managed by a team of more than 900 employees.
The annual production capacity of the Tabuk plant is around 1.6 billion (Base Unit Measurement) including dry oral suspensions, oral liquids, semisolids, and vials.
This manufacturing site is located in the second industrial city of Dammam in the Kingdom of Saudi Arabia. The site area is about 14,000 square meters and the built-up area is about 17,000 square meters. The plant’s high standards of quality and automation at various stages of the manufacturing process have led to its classification as one of the most advanced manufacturing sites in the region. A specialized section of the Dammam site has been allocated for injectables. This has enabled Tabuk Pharmaceuticals to further penetrate the Saudi and regional markets with new medications including contrast media used in medical imaging, in addition to general anesthetics. Dammam plant is the first manufacturing facility in the Kingdom of Saudi Arabia to manufacture lyophilized vials. The plant also manufactures other pharmaceutical preparations such as creams, ointments, nasal sprays, and other liquid dosage forms. This site is managed by a team of more than 200 employees.
The annual production capacity of this plant is around 50 million (Base Unit Measurement) including liquid vials, lyophilized vials, and ampoules.
This manufacturing site is located in Blida, Algeria. The total area of the site is about 6200 square meters, and the facility has a built-up area of more than 3000 square meters. This site is currently manufacturing oral solid dosage forms (tablets and capsules). Current and future plans aim to expand its scope of work to include new production lines, enabling it to manufacture other pharmaceutical products such as liquid preparations and nasal sprays. This site is managed by a team of more than 60 employees.
The annual production capacity of this site is around 150 million (Base Unit Measurement) including oral solids, liquid bottles, and nasal preparations.
This site is located in the industrial zone in the north of Khartoum in Sudan. The total area of the site is about 8,500 square meters, and the built-up area of the facility is about 6,500 square meters. The plant supplies the local market with many pharmaceutical dosage forms such as tablets, capsules, and liquid preparations. This site is managed by a team of more than 200 employees.
The annual production capacity of the site is around 260 million (Base Unit Measurement) including oral solids and liquid bottles.